Latest / Deep Dive Ortho — Orthopaedic Surgery, AI & Digital Health Podcast. / Frozen Shoulder

Transcript

Frozen Shoulder · Deep Dive Ortho — Orthopaedic Surgery, AI & Digital Health Podcast.

0:00
Welcome to the Deep Dive. Today, we're delving
0:02
into a condition that, well, it so often perplexes
0:05
both the patients experiencing its grip and,
0:08
frankly, us clinicians striving to unravel its
0:11
mystery, the frozen shoulder. It's a common enough
0:15
presentation, isn't it? Yet it can be profoundly
0:17
debilitating, really disrupting a patient's daily
0:19
life. Simple actions like reaching for a cup
0:22
or getting dressed can become arduous, painful
0:24
challenges. We are, of course, talking about
0:26
adhesive capsulitis. Now, this condition presents
0:29
quite a complex puzzle. From its insidious onset,
0:32
it's often prolonged journey through quite distinct
0:35
phases and the nuanced approaches required for
0:38
effective diagnosis and treatment. To guide us
0:40
through this intricate landscape, we are incredibly
0:42
fortunate to have with us today, Professor Mo
0:44
Imam. With his extensive experience and deep
0:47
insight in orthopedic surgery, he's perfectly
0:49
positioned to help us thoroughly explore this
0:51
topic. Our mission today, then, is to unpack
0:53
the current understanding, the clinical presentation,
0:56
and the evidence -based management strategies
0:58
for adhesive capsulitis. We hope to provide you,
1:01
our fellow medical professionals, with valuable
1:03
insights to refine your approach to this often
1:05
challenging condition. So to begin, perhaps we
1:09
could just unpack this a little. What exactly
1:11
are we referring to when we speak of frozen shoulder
1:14
or adhesive capsulitis? I mean, these terms are
1:16
often used interchangeably, aren't they? But
1:18
what's the precise definition and maybe more
1:21
importantly, the core pathology underlying it?
1:23
That's absolutely the right place to start. Adhesive
1:25
capsulitis is precisely defined as a chronic
1:30
fibrosin condition of the shoulder. What characterizes
1:33
it is an insidious and progressive, quite severe
1:36
restriction of both active and passive shoulder
1:38
range of motion. And crucially, this occurs without
1:41
any known intrinsic disorder of the shoulder
1:44
joint itself. So you can really think of it as
1:46
the shoulder joint, well, almost literally freezing
1:49
up. The core pathology you see involves an initial
1:52
inflammatory process within the joint capsule.
1:54
This inflammation then seems to trigger what
1:57
we call fibroblastic proliferation. So the connective
2:00
tissue cells multiplying. Exactly. These fibroblasts
2:03
start multiplying excessively, and this leads
2:05
to a significant thickening of the joint capsule
2:07
itself, the development of fibrosis, essentially
2:10
scar tissue, and quite problematically, an adherence
2:13
of the capsule to itself and also to the humerus.
2:16
This whole process ultimately creates a mechanical
2:18
block, severely restricting the shoulder's ability
2:20
to move. So understanding this... Ascite inflammatory
2:24
and fibrotic process helps us grasp why timing
2:27
interventions carefully is so important. That
2:29
makes sense. And while frozen shoulder is the
2:31
term most people know, you'll also hear it called
2:34
a stiff shoulder or contracted shoulder in clinical
2:37
settings. What's often surprising, perhaps, is
2:39
that it's generally considered a self -limiting
2:41
condition. It tends to resolve on its own, typically
2:44
within, say, 18 to 24 months. Which sounds reassuring
2:48
initially. It does. But it's vital to acknowledge
2:51
that it isn't always a straightforward resolution
2:53
for everyone. Some reports indicate that a, well,
2:57
a significant proportion of patients, perhaps
2:59
anywhere from 20 % up to 50%, can experience
3:02
residual pain and limited range of motion lasting
3:05
for several years beyond that typical timeframe.
3:07
Years, really? Yes, potentially. So while a natural
3:11
sawing process often occurs, it can still be
3:13
a very long and challenging journey for many
3:15
patients. That's certainly important to highlight
3:17
that idea that not every patient simply thaws
3:19
out. completely, and that extended recovery can
3:22
be incredibly frustrating for them. Now moving
3:25
on, who typically experiences this condition?
3:28
Are there any specific demographics or predisposing
3:32
factors we should be particularly aware of, you
3:35
know, common patient profiles that might raise
3:37
our index of suspicion? Absolutely. Understanding
3:40
the epidemiology gives us a much clearer picture
3:42
of who's most susceptible. It affects approximately
3:45
2 % to 5 % of the general population. So, reasonably
3:48
common in practice? Reasonably common, yes. You'll
3:51
certainly encounter it. In terms of demographics,
3:53
we do see a slight predominance among women.
3:56
The ratio is about 1 .4 to 1 compared to men.
3:59
The most common age of onset is typically between
4:02
40 and 70 years, with the mean age hovering around
4:04
55. Now, a significant point for your practice
4:07
is that individuals younger than 50 seem to be
4:10
at a higher risk for bilateral disease. Affecting
4:12
both shoulders. Yes, affecting both shoulders.
4:16
That can occur in up to 40%, even 50 % of cases
4:19
in that younger group. When it's unilateral,
4:22
the non -dominant arm is, interestingly, more
4:25
often affected, although why that is remains
4:27
a bit of a question. That is interesting. Now,
4:30
perhaps the most crucial risk factors are the
4:32
associated comorbidities. The link with diabetes
4:35
mellitus, both type 1 and type 2, is particularly
4:37
strong. Very strong indeed. The prevalence of
4:41
adhesive capsulitis in diabetic patients can
4:43
be as high as, well, figures range from 10 .3
4:46
% up to 22 .4%. That's significantly higher than
4:50
in the general population. Wow, that's a huge
4:52
difference. It is. And it's not just a statistic.
4:54
For your diabetic patients, it fundamentally
4:56
alters the prognosis discussion. It's also worth
4:59
noting that shoulder stiffness might even be
5:00
the first sign of diabetes in some patients.
5:02
Really? presenting with a stiff shoulder first.
5:05
It can happen, which should absolutely prompt
5:07
you to do a further workup for diabetes if you
5:10
encounter that sort of presentation. What's also
5:12
clear from the data is that outcomes for diabetic
5:15
patients are generally worse, regardless of the
5:17
treatment approach. They have a higher risk for
5:20
bilateral disease, too. And this risk seems to
5:23
increase further with older age, a longer duration
5:26
of diabetes, the presence of autonomic neuropathy,
5:29
and a history of myocardial infarction. It really
5:32
points towards broader systemic factors being
5:35
involved. So optimizing their glycaemic control
5:38
becomes part of the shoulder management strategy
5:40
almost. Absolutely. It isn't just good general
5:42
medical care. It's a direct intervention potentially
5:45
influencing their shoulder recovery. Beyond diabetes,
5:48
thyroid disorders, both hypo and hyperthyroidism,
5:51
are also significant risk factors. These are
5:53
often linked to an underlying autoimmune etiology.
5:56
Patients with hyperthyroidism, for instance,
5:59
have about 1 .22 times the risk of developing
6:02
adhesive capsulitis, again, highlighting this
6:05
systemic connection. It's fascinating how interconnected
6:07
it all is. It really is. Then we have trauma
6:10
and immobilization, which are also well -established
6:12
triggers. This could be following something like
6:15
a proximal humerus fracture or simply prolonged
6:18
immobilization after other upper limb injuries
6:20
or even post -surgical complications. We see
6:23
it after procedures like rotator cuff repair.
6:26
care, axillary dissection for malignancy, or
6:28
even chest wall surgery. Which really underlines
6:31
the importance of early movement post -op or
6:33
post -injury. Critically important. Early gentle
6:36
mobilization is a key preventive measure here.
6:39
We often say motion is lotion, and that certainly
6:41
applies in trying to prevent stiffness setting
6:43
in. Other associated conditions pop up, too.
6:47
DuPoitrin's disease, for example, there's quite
6:48
a striking association there, with some studies
6:51
finding over 50 % of adhesive capsulitis patients
6:53
also having DuPoitrin's. We also see links, perhaps
6:57
less strongly defined but still present, with
6:59
atherosclerotic disease, cervical disc disease,
7:02
Parkinson's disease, and various cardiac conditions.
7:05
Even cerebrovascular disease has been implicated.
7:07
It's quite a diverse list. It is. And finally,
7:10
there's growing evidence suggesting a genetic
7:12
predisposition. Studies have looked at links
7:15
to things like HLA -B27 positivity and specific
7:18
gene polymorphisms, like for IL -6 and MMP3.
7:22
This genetic component might help explain why
7:25
some individuals just seem inherently more susceptible
7:27
to this fibrotic process, even without an obvious
7:30
external trigger. That paints a remarkably comprehensive
7:33
picture of the risk factors and those surprising
7:35
systemic connections. Given all that, what's
7:38
actually going on inside the shoulder? What triggers
7:40
this fibrotic process at the cellular and molecular
7:42
level? What are the underlying mechanisms? Right,
7:45
this is where we get into the nitty -gritty of
7:48
the etiology, pathophysiology, and histopathology.
7:52
It's helpful first to differentiate between two
7:54
main types. We talk about primary adhesive capsulitis,
7:58
which is often labeled idiopathic. This form
8:01
occurs without an obvious precipitating event.
8:04
It's thought to arise from some sort of intrinsic
8:06
inflammatory process within the joint that then
8:09
leads on to these fibrotic changes. And it's
8:11
often this primary type that's associated with
8:13
those systemic conditions we just discussed,
8:16
like diabetes and thyroid disorders, suggesting
8:18
perhaps an underlying systemic inflammatory or
8:21
even autoimmune component. Okay, so that's the
8:24
out of the blue type. In essence, yes. In contrast,
8:27
secondary adhesive capsulitis results from a
8:29
clear external event or condition that directly
8:31
impacts shoulder mobility. Common triggers here
8:34
would be significant trauma leading to immobilization,
8:37
perhaps post -operative complications after shoulder
8:39
or even chest wall surgeries, or simply prolonged
8:41
immobilization after any injury or procedure
8:44
affecting the arm. Making that distinction is
8:46
vital when taking the patient's history. Understood.
8:48
And the actual process within the joint. The
8:51
path of physiology itself is, well, it's a fascinating
8:54
interplay. It kicks off with an initial inflammatory
8:57
response. This is what's thought to be responsible
9:00
for the pain and the early limitation of motion,
9:03
particularly during that initial freezing phase.
9:06
Following that inflammation, the fibrotic changes
9:08
really take hold. These changes seem to concentrate
9:11
particularly within the rotator interval. That
9:13
specific area in the front of the shoulder? Precisely.
9:16
It's a critical triangular region of the capsule
9:19
between the supraspinatus and subscapularis tendons.
9:22
Within this interval, we see significant thickening
9:26
of the coraco -humeral ligament, the CHL, which
9:28
is a key structure there, and a general contraction
9:31
or shrinking of the joint capsule. Imaging studies
9:34
like MRI often visualize these changes. You might
9:37
see a reduced joint capsule volume, maybe some
9:39
thickening of the synovial lining. At the cellular
9:42
level, this fibrotic process is driven by the
9:44
proliferation of fibroblasts and their transformation
9:47
into myofibroblasts. These are cells that have
9:50
characteristics of both fibroblasts and smooth
9:52
muscle cells, meaning they can contract. Ah,
9:54
so they actively pull things tighter. They contribute
9:57
to that, yes. These cells, along with an abundant
10:00
deposition of type 3 collagen, which is more
10:03
like scar tissue collagen, contribute significantly
10:05
to the mechanical block that restricts motion.
10:08
It's generally understood that the essential
10:10
lesion, the core problem area, involves the coricohumeral
10:14
ligament and that rotator interval capsule. The
10:16
CHL in particular becomes incredibly stiff and
10:19
gets put under tension during external rotation,
10:22
making it a key anatomical target for any intervention
10:25
aimed at restoring movement. So that's a real
10:27
focus area. Definitely. Furthermore, we observe
10:29
an altered balance of matrix metalloproteinases
10:32
MMPs, and they're inhibitors, tissue inhibitors,
10:36
of metaloproteinases, Natempis. Now, these are
10:38
enzymes responsible for breaking down and remodeling
10:41
the extracellular matrix, including collagen.
10:44
In adhesive capsulitis, this delicate balance
10:46
is disrupted. It suggests that collagen production
10:48
is outstripping its degradation, leading to that
10:51
excessive scar tissue formation. An imbalance
10:53
in breakdown and buildup. Exactly. The initial
10:56
inflammatory phase is supported by the finding
10:59
of over -expression of various inflammatory cytokines,
11:02
things like IL -1, IL -1, TNFX, COX -1, QOX -2,
11:06
particularly in the bursal tissues. Mass cells,
11:09
which are inflammatory cells known to regulate
11:11
fibroblast activity, are often found in the affected
11:14
tissues. They're thought to act as intermediaries.
11:17
bridging that initial inflammatory response and
11:19
the subsequent fibrotic processes. Interesting
11:22
cell type to be involved. Yes, and delving even
11:24
deeper into potential molecular links, researchers
11:27
have found elevated levels of intercellular adhesion
11:29
molecule 1, ICAM -1, in the capsular tissue,
11:32
synovial fluid, and even the serum of patients
11:35
with adhesive capsulitis. What's intriguing is
11:38
that ICAM -1 levels are also elevated in diabetes
11:40
mellitus. This offers a potential molecular connection,
11:43
a possible reason why these two conditions are
11:45
so frequently linked. Like the potential biological
11:47
bridge. Possibly. We also see elevated nerve
11:50
growth factors, which helps explain the often
11:52
severe pain patients experience, particularly
11:54
in the early stages. And critically, transforming
11:57
growth factor beta, or TGFU, seems to play a
12:00
pivotal role in inducing this arthrofibrosis.
12:03
Animal models have shown that over -expressing
12:05
TGFO can rapidly lead to conditions that look
12:08
very much like adhesive capsulitis. So TGFO is
12:11
a major player in the fibrosis. It appears to
12:13
be a key driver, yes, which makes it a significant
12:16
focus for potential future targeted therapies.
12:19
So putting it all together, on a hiscopathological
12:21
level, what you'd see under the microscope, the
12:23
affected shoulder, is characterized by synovial
12:25
hyperplasia and overgrowth of the synovial lining.
12:29
Angiogenesis, formation of new blood vessels,
12:32
often seen in inflammation and healing, and ultimately
12:34
significant joint capsule fibrosis. Clinically,
12:37
this translates to a palpably thickened and contracted
12:40
joint capsule. When surgeons look inside arthroscopically,
12:44
they confirm these observations. They see subacronial
12:47
fibrosis, proliferative synovitis, and that distinct
12:50
capsular thickening. It's really quite a complex
12:53
cascade, isn't it? From that initial inflammation
12:55
right through to a profound fibrotic state -restricting
12:57
movement. That detailed understanding of the
13:00
underlying biology really helps to demystify
13:02
what's happening internally. You know, patients
13:04
often describe a very distinct progression with
13:06
this condition, almost like a story that unfolds
13:09
over time. Could you walk us through the typical
13:11
stages they experience, what defines each one,
13:13
and what should we perhaps prepare our patients
13:14
for? Absolutely. The clinical course of adhesive
13:17
capsulitis is often described in three distinct
13:20
phases. It's vital, though, to remember that
13:22
the duration and the intensity of symptoms can
13:25
vary quite significantly among individuals. of
13:28
typical guidelines rather than rigid rules, if
13:30
you like. Understood. The first is the freezing
13:32
or painful stage. This typically lasts anywhere
13:35
from, say, six weeks up to nine months, though
13:38
for some, the gradual onset of pain might be
13:40
shorter, perhaps one to three months. During
13:42
this phase, patients experience that gradual
13:45
onset of diffuse disabling shoulder pain. It's
13:48
often insidious appearing without a clear injury,
13:50
and it characteristically worsens at night. Difficulty
13:53
sleeping is a very common complaint. Yes, the
13:56
night pain seems particularly troublesome. It
13:58
really does. The pain is usually described as
14:00
a dull ache, sometimes radiating into the biceps
14:03
area. As this pain intensifies, our movement
14:06
becomes progressively limited. Pathologically,
14:09
this corresponds to those early inflammatory
14:11
changes and active synovitis we were just discussing.
14:14
Okay, so intense pain and increasing stiffness.
14:17
Exactly. Following this, we enter the frozen
14:19
or stiff stage. This phase can last quite a while
14:22
from 4 to 12 months, sometimes even longer. Here,
14:25
the intensity of the pain often lessens compared
14:28
to the freezing stage. It might still be there,
14:31
especially at end range, but stiffness and significant
14:34
motion limitations become the primary concern
14:36
for the patient. They experience profound capsular
14:39
rigidity. This progressively restricts their
14:42
range of motion across all planes, flexion, abduction,
14:45
rotation, severely impacting their ability to
14:47
perform activities of daily living. Things like
14:50
reaching into a cupboard, getting dressed, fastening
14:52
a seatbelt become incredibly challenging, sometimes
14:54
impossible. So the pain might ease slightly,
14:56
but the stiffness really takes hold. That's the
14:59
hallmark of this stage. It represents the peak
15:01
of those fibrotic changes and the capsular contraction.
15:05
Finally, we have the thawing stage. This is the
15:07
recovery phase. It typically lasts from 5 to
15:10
26 months, though again, it can sometimes be
15:12
as short as 1 to 3 months for some lucky individuals.
15:15
During this period, patients notice a gradual
15:18
reduction in pain and a slow, gradual return
15:20
of motion begins. While improvement certainly
15:23
occurs, it's crucial we manage expectations here.
15:26
Because it's not always a full return. Exactly.
15:30
Complete recovery, meaning a full return to their
15:32
preconditioned motion and function, is unfortunately
15:34
relatively rare. Studies suggest that approximately
15:38
7 % to 15 % of patients may experience some permanent
15:42
loss of motion, and perhaps 10 % to 20 % experience
15:45
residual symptoms, including some stiffness and
15:48
discomfort even after the condition has largely
15:50
run its course. So it really paints a picture
15:53
of quite a prolonged battle for many people.
15:55
From that initial painful freezing where motion
15:58
is actively seized through the rigid frozen stage
16:01
and then that slow, often frustrating thaw. That's
16:04
a very good way to put it. It's often a marathon,
16:06
not a sprint. That long tail of recovery where
16:08
a complete return to baseline isn't guaranteed
16:10
for everyone is certainly important for patient
16:13
counseling. Now thinking about the clinic, when
16:16
a patient walks in and you suspect adhesive capsulitis,
16:20
What are the key symptoms we should be listening
16:22
for? And what's really crucial in our physical
16:25
examination to confirm those suspicions and rule
16:27
out other potential issues, what are the absolute
16:30
must -dos during that initial assessment? You're
16:33
right. The history and the physical examination
16:35
are absolutely paramount for making this diagnosis.
16:38
When a patient presents, we're listening for
16:39
that characteristic insidious onset of shoulder
16:42
pain, often worsening at night. They'll invariably
16:45
report a dull, poorly localized pain, perhaps
16:49
radiating into the biceps area. They'll almost
16:51
certainly describe significant difficulty with
16:53
overhead movements or reaching behind their back,
16:56
things that profoundly impact their daily activities.
16:59
And that pain progression is a key indicator,
17:01
typically very severe and sharp in the initial
17:03
freezing stage, transitioning to more of a dull
17:05
ache with sharp pains only at the extremes of
17:08
motion during the frozen stage. Okay, so history
17:10
is key. What about the examination? The physical
17:13
examination is truly the hallmark for diagnosis
17:16
here. What we're looking for is a symmetric loss
17:18
of both active and passive range of motion across
17:21
all planes. That means flexion, abduction, external
17:25
rotation, and internal rotation. Both active
17:28
and passive. That's critical, isn't it? Absolutely
17:30
critical. This symmetric restriction, meaning
17:33
the patient cannot move the arm themselves and
17:36
you cannot move it for them beyond a certain
17:38
point, is a key differentiating factor for many
17:41
other shoulder pathologies where passive motion
17:44
might be preserved even if active motion is painful
17:47
or weak. It's also vital to document all the
17:50
motion planes and always compare them to the
17:52
unaffected contralateral side. And a really significant
17:55
clinical pearl is that the external rotation
17:58
deficit is often the most common and the earliest
18:00
finding. If you find that external rotation is
18:03
relatively preserved, your suspicion for adhesive
18:06
capsulitis should probably decrease significantly.
18:08
That's a very useful tip. As you move the arm
18:10
passively, you'll typically encounter what's
18:13
described as a tethered endpoint to motion. It
18:16
feels like the joint is mechanically blocked,
18:18
almost like hitting a taut rope, rather than
18:20
the patient simply stopping you due to pain.
18:22
though pain might also be present. You might
18:25
also find diffuse tenderness around the joint
18:27
upon palpation. On inspection, look for any muscle
18:30
atrophy from disuse, or perhaps prior surgical
18:33
scars if you're suspecting a secondary cause.
18:36
And crucially, in true adhesive capsulitis, distal
18:39
neurological function sensation and motor power
18:41
in the hand and wrist should remain intact. This
18:44
is a vital finding that helps us differentiate
18:46
it from neurological issues like cervical radiculopathy.
18:49
Right, checking the neurology is essential. Absolutely.
18:52
Regarding provocative tests, things like impingement
18:55
tests, nearer Hawkins, biceps tests, speed, maybe
18:59
even SLAP maneuvers. These may often be positive,
19:02
simply due to the altered mechanics and inflammation.
19:05
However, it's important to recognize that proper
19:08
rotator cuff strength testing might actually
19:10
be quite limited because of the significant loss
19:12
of motion. You simply can't get the arm into
19:14
the required positions. What's absolutely vital,
19:17
though, is to try and rule out cervical spine
19:19
radiculopathy as the primary source of the pain.
19:22
A negative spurling maneuver is very helpful
19:24
in that regard. Really, the combination of that
19:27
characteristic history and the finding of symmetric
19:29
global loss of both active and passive motion
19:32
is often enough to strongly suspect adhesive
19:34
capsulitis. Hashtag tag tag diagnostic precision
19:37
and differential considerations. That detailed
19:39
clinical picture is immensely helpful. So with
19:41
that clinical suspicion firmly established, what
19:44
are our next steps in actually confirming the
19:46
diagnosis and crucially ruling out other underlying
19:49
issues? How do we best utilize things like laboratory
19:52
tests and imaging in this process? Indeed. While
19:55
the diagnosis of adhesive capsulitis is primarily
19:58
clinical based on that history and examination,
20:01
a thorough evaluation often involves other modalities.
20:04
These help to solidify the picture, or perhaps
20:07
more importantly, to rule out other conditions
20:09
that could be masquerading as frozen shoulder.
20:12
Let's first address laboratory tests. Routine
20:15
lab testing is generally not indicated for directly
20:18
diagnosing adhesive capsulitis itself. There's
20:21
no specific blood marker for it. However, if
20:24
you suspect an underlying systemic condition
20:26
might be contributing, particularly diabetes
20:28
or thyroid disease, then appropriate blood tests
20:30
become crucial. Like checking TSH or HbA1c. Exactly.
20:35
Checking TSH for thyroid function or HbA1c for
20:38
diabetes helps identify or monitor these factors,
20:41
which as we discussed, can significantly influence
20:44
the disease's progression and treatment outcomes.
20:47
So it's really about looking for those associated
20:49
comorbidities, not for a direct marker of the
20:51
frozen shoulder itself. Right, looking for the
20:53
bigger picture. What about imaging? Now onto
20:55
imaging. Radiographs, simple x -rays, are an
20:58
essential initial step. They are primarily used
21:01
to rule out other bony abnormalities, things
21:03
like significant osteoarthritis, perhaps a missed
21:06
posterior dislocation, or any pre -existing surgical
21:09
hardware that might be causing symptoms. In very
21:12
prolonged cases, you might occasionally see some
21:14
disused osteopenia, a thinning of the bone. But
21:17
often, the x -rays are remarkably normal. So
21:19
x -rays are mostly for ruling things out? Primarily,
21:22
yes. Magnetic resonance imaging, MRI, sometimes
21:25
with arthrography, where contrast is injected
21:27
into the joint, is not strictly necessary for
21:29
diagnosing adhesive capsulitis. The diagnosis
21:31
is clinical. But MRI can be incredibly valuable.
21:34
In what way? Well, it helps evaluate for other
21:37
underlying shoulder pathologies that might mimic
21:39
the symptoms, like a rotator cuff tear or labral
21:42
pathology. It can also help confirm the severity
21:45
of the capsular involvement in adhesive capsulitis.
21:48
Typical MRI findings you might see include a
21:50
loss or obliteration of the axillary recess,
21:53
that little pouch at the bottom of the joint,
21:54
which directly indicates capsular contracture.
21:57
You might also see a thickened coracohumeral
21:59
ligament, often measuring four millimeters or
22:01
more, and a thickened rotator interval capsule.
22:04
frequently seven millimeters or more. So quite
22:06
specific signs of that thickening and shrinking.
22:09
Yes, exactly. These findings correlate with reduced
22:12
joint capsule volume and can also show proliferative
22:14
synovitis or even fibrosis in the subacromial
22:18
space. Ultrasound can also be a useful adjunct.
22:21
It's readily available and non -invasive. It
22:23
might reveal thickening of the joint capsule,
22:25
particularly in the rotator interval, and can
22:27
sometimes demonstrate limited sliding movement
22:30
of the supraspinatus tendon beneath the acrimand,
22:33
which aligns with that physical restriction.
22:35
It's also very useful for guiding injections
22:37
accurately. That makes sense. Lastly, a diagnostic
22:40
injection test can be very informative in certain
22:42
situations. This involves administering a local
22:45
anesthetic typically something like 1 % lidocaine,
22:48
into the subacromial space, or sometimes the
22:51
glenohumeral joint itself. The key differentiating
22:54
factor in true adhesive capsulitis is that the
22:57
restriction of range of motion persists even
23:00
after the injection has provided significant
23:02
pain relief. Ah, so the mechanical block remains
23:05
even when the pain is numb. Precisely. This helps
23:08
differentiate it from conditions like subacromial
23:10
bursitis or rotator cuff tendinopathy where the
23:13
pain and often some associated limitation in
23:16
range of motion might significantly improve once
23:18
the anesthetic takes effect. That persistence
23:21
of mechanical restriction despite pain relief
23:23
is a strong indicator of true capsular contracture,
23:26
true adhesive capsulitis. That's a very clear
23:29
diagnostic pathway. It does raise an important
23:31
question though. What other conditions might
23:33
present similarly? How do we reliably distinguish
23:36
them from adhesive capsulitis to ensure we get
23:38
the management right and avoid those common misdiagnosis
23:41
pitfalls? What should be high on our differential
23:43
list? That's an excellent and absolutely critical
23:46
question because, as you say, a misdiagnosis
23:48
can lead to inappropriate treatment, ineffective
23:51
interventions, and ultimately prolong the patient's
23:54
suffering. While adhesive capsulitis has its
23:56
hallmark features, several other shoulder pathologies
23:59
can certainly present with pain and restricted
24:01
movement, making a careful differential diagnosis
24:04
essential. So what should we be thinking about?
24:08
Right, here's a list of conditions we must always
24:10
consider. First, posterior glenohumeral dislocation.
24:14
This can cause significant pain and limitation,
24:17
but usually there's a clear traumatic event,
24:20
and specific radiographic findings would be pretty
24:23
evident on x -ray if you look carefully. Rotator
24:25
cuff pathology, injury, tear, or arthropathy.
24:29
Tears cause pain and weakness, especially with
24:31
active motion. While they might limit active
24:34
range, passive range of motion is often preserved
24:37
or only minimally affected. That's a key differentiator
24:40
from adhesive capsulitis, where both active and
24:42
passive ROM are severely restricted globally.
24:45
That active versus passive distinction again.
24:48
Crucial. Subacromial rotator cuff impingement.
24:52
This typically causes pain with overhead movements,
24:54
often in a specific arc, but not usually the
24:57
global restriction of motion seen in frozen shoulder.
25:00
A diagnostic injection can be very helpful here,
25:03
as the pain would likely improve significantly
25:04
after the anesthetic. Glenohumeral arthritis.
25:08
Yes, it causes stiffness and pain, but it's primarily
25:11
due to joint space narrowing and osteophytes
25:13
bony spurs, which are clearly visible on x -rays.
25:17
The pattern of emotional loss might also differ,
25:18
and the history usually involve more chronic
25:21
degenerative -type pain rather than that distinct
25:23
freezing frozen thawing pattern. Avascular necrosis
25:27
of the shoulder is necrosis or death of bone
25:29
tissue due to lack of blood supply. It's painful,
25:32
but imaging, particularly MRI, is key for diagnosis.
25:36
Neuropathic Charcot joint. This is a severe progressive
25:39
joint destruction resulting from nerve damage.
25:41
It's rare in the shoulder but causes marked instability
25:43
and destruction, very different from the stiffness
25:45
of adhesive capsulitis and obvious unimaging.
25:49
Cervical disc disease or radiculopathy. Nerve
25:51
compression in the neck can absolutely refer
25:53
pain to the shoulder and arm and cause weakness.
25:56
However, the passive range of motion of the shoulder
25:58
joint itself often remains relatively preserved.
26:01
Testing neck movements and performing tests like
26:04
the Spurling maneuver are vital here. Checking
26:06
the neck is always important with shoulder pain.
26:09
Always. Biceps issues like subluxation or tendonitis.
26:13
These cause pain along the biceps tendon, often
26:15
worsened by specific movements, but don't typically
26:17
lead to that global symmetric loss of passive
26:19
and active motion. SLAP lesions, tears, and labrum
26:22
often cause pain with overhead activities, maybe
26:25
some clicking or popping, but again, not the
26:27
profound global stiffness. And finally, Multi
26:30
-directional shoulder instability, DI. This involves
26:33
excessive laxity in multiple directions, leading
26:36
to a feeling of instability or the shoulder slipping,
26:39
rather than the profound stiffness characteristic
26:41
of adhesive capsulitis. But to reiterate, the
26:44
absolute hallmark feature that helps differentiate
26:46
adhesive capsulitis from many, if not all, of
26:49
these other shoulder pathologies is that marked
26:51
reduction in both active and passive range of
26:53
motion in multiple planes, especially external
26:55
rotation. If a patient presents with significant
26:58
shoulder pain and they can't lift their arm actively,
27:00
but you can passively move it through a near
27:02
normal range, even if it's painful for them,
27:04
then it's highly unlikely to be adhesive capsulitis.
27:07
That global symmetric restriction of both active
27:10
and passive motion. is the diagnostic cornerstone
27:13
we rely on. You really can't overstate its importance.
27:16
Never forget that difference. That's incredibly
27:18
helpful for navigating the diagnostic maze. Right
27:21
then, let's turn our attention to treatment.
27:23
Once we've confidently diagnosed adhesive capsulitis,
27:26
what's the initial approach? What does the current
27:29
understanding suggest for non -surgical options?
27:32
I understand these are often the mainstay, aren't
27:33
they? Indeed they are. Non -surgical treatments
27:36
are generally the first line of defense, and
27:38
actually they're often remarkably effective.
27:41
The primary focus here is really twofold, controlling
27:45
the pain effectively and diligently working to
27:48
restore motion and eventually strength. And it's
27:51
also critical, as we touched on earlier, to optimize
27:53
any underlying health conditions that might be
27:55
contributing, especially in diabetic patients.
27:58
Ensuring their glucose control is as good as
28:00
it can be can significantly aid the shoulder's
28:03
recovery. That's a point we really can't overstate.
28:05
A holistic view from the start. Absolutely. Now,
28:08
physical therapy, or physiotherapy, is undeniably
28:11
the cornerstone of treatment. It's all about
28:14
gentle, pain -free, progressive stretching. Often
28:17
incorporating moist heat beforehand can help
28:19
prepare the tissues. This could be supervised
28:22
therapy, perhaps initially, or a well -structured
28:25
home exercise program that the patient follows
28:27
diligently. While supervised sessions are often
28:30
recommended for, say, three to six months, there's
28:32
actually some ongoing debate about the optimal
28:34
intensity. Oh, more isn't always better. Not
28:38
necessarily. Some evidence suggests that a gentle
28:40
thawing approach, or even what's sometimes termed
28:43
supervised neglect, with very gentle exercises
28:46
like pendulum swings, can be equally effective
28:48
or perhaps even superior to more intensive painful
28:52
physical therapy, particularly in the early stages.
28:55
High rates of satisfactory outcomes have been
28:57
shown with quite simple stretching programs.
28:59
That's interesting. So pushing through intense
29:00
pain might be counterproductive? It certainly
29:02
might be, especially in that early inflammatory
29:04
freezing stage. The focus should be on gent -
29:07
persistent stretching within tolerable limits.
29:10
Specific exercises like the external rotation
29:13
passive stretch using a doorway, forward flexion
29:15
done lying supine, and the crossover arm stretch
29:18
are common examples. These exercises can sometimes
29:21
be combined with other modalities provided by
29:23
the therapist things like ultrasound, electrical
29:25
stimulation, manual therapy techniques, shortwave
29:28
diathermy, low -level laser therapy, even hydrotherapy
29:32
primarily to help enhance pain relief and facilitate
29:34
movement. For instance, posterior glide mobilization
29:37
techniques are often used and considered effective
29:39
for improving external rotation. Okay, so physiotherapy
29:42
is key. What about medications? For pharmacological
29:45
therapy, the goal is primarily symptomatic management,
29:49
really supporting those physical therapy efforts
29:51
by making the exercises more tolerable. Non -steroidal
29:54
anti -inflammatory drugs, NSAIDs, are commonly
29:57
recommended for short -term pain relief. They're
30:00
particularly useful in the early, more inflammatory
30:03
stages as they target the underlying synovitis.
30:06
However, while they help with pain, studies haven't
30:08
consistently shown significant objective improvements
30:11
in shoulder mobility with NSAIDs alone. So they
30:14
help manage symptoms, but don't fix the stiffness
30:16
itself. Broadly speaking, yes. Systemic oral
30:19
corticosteroids, like a short course of prednisone
30:22
or prednisolone, can lead to a faster improvement
30:25
in pain and disability in the short term. However,
30:28
this benefit may not be sustained beyond, say,
30:30
six weeks, and there's always a potential for
30:33
rebound symptoms once the medication is stopped.
30:35
Plus, the systemic side effects need consideration.
30:38
So it's often seen as a short -term bridge, not
30:41
a long -term solution. Interarticular corticosteroid
30:44
injections directly into the glenohumeral joint
30:46
often offer faster and potentially superior improvement
30:49
in symptoms compared to oral steroids. They work,
30:52
we think, by decreasing the fibromatosis and
30:54
the presence of those myofibroblasts within the
30:56
shoulder capsule. Targeting the inflammation
30:58
and fibrosis locally. Exactly. While they can
31:01
provide rapid pain relief and improve ranging
31:03
motion, the long -term difference compared to
31:05
physiotherapy alone might not be sustained, perhaps
31:08
at six months or a year. Some studies show that
31:11
while injections might improve self -assessed
31:13
disability at six weeks, physiotherapy might
31:16
specifically improve passive external rotation
31:18
more effectively. Interestingly, combining both
31:21
doesn't always seem to lead to significantly
31:24
better long -term benefits than either modality
31:27
alone in some studies. So injection gives quick
31:29
relief, but long -term gains might come more
31:31
from the physio. That's a reasonable summary
31:33
of some of the evidence, yes. Though injections
31:36
can certainly facilitate participation in physio.
31:40
Sodium hyaluronate intraarticular injection is
31:43
another option. This is sometimes called viscose
31:45
supplementation. It's considered chondroprotective,
31:48
helping protect cartilage. Studies have shown
31:50
it can provide outcomes equivalent to corticoceroid
31:53
injections in terms of range of motion, pain,
31:57
and functional scores in the short term. It also
31:59
appears quite safe. There's some evidence suggesting
32:02
that a combined injection of sodium hyaluronate
32:04
with a steroid alongside physiotherapy might
32:08
yield better overall improvements in both pain
32:10
and joint motion compared to just steroid and
32:12
physiotherapy alone. That combination approach
32:15
is interesting. Multiple agents working together,
32:17
potentially. Potentially, yes. Then we have nerve
32:19
blocks, specifically the suprascapular nerve
32:21
block, SSNB. This is a really valuable tool in
32:24
my view. The suprascapular nerve supplies sensation
32:26
to about 70 % of the glenocumeral joint. So blocking
32:29
it provides significant, albeit temporary, pain
32:32
relief. Allowing a window for movement. Precisely.
32:35
This can be critical in facilitating mobilization
32:38
and enabling more effective physical therapy.
32:41
It allows patients to push through stiffness
32:43
that intense pain would otherwise completely
32:45
prevent. Studies show improved short -term pain,
32:48
and some evidence suggests better pain control
32:50
and range of motion even at three months compared
32:52
to intraarticular steroids alone. Using ultrasound
32:56
or EMG guidance for the block seems to be more
32:58
effective than landmark -based approaches. And
33:01
finally, there's hydrodilation. also known as
33:03
distension arthrography or brisement. This involves
33:06
injecting a large volume of sterile fluid, typically
33:09
saline, often mixed with a corticosteroid and
33:12
local anesthetic into the joint under imaging
33:14
guidance, like fluoroscopy or ultrasound. Physically
33:17
stretching the capsule from the inside. That's
33:19
the idea. It aims to mechanically stretch the
33:22
contracted capsule. potentially disrupting some
33:24
adhesions and increasing the intracapsular volume.
33:27
The cortisone provides an anti -inflammatory
33:29
effect too. It can certainly improve pain and
33:32
disability, especially in the short to medium
33:34
term, say 3 to 12 weeks. Though again, some longer
33:37
term studies suggest it may show no significant
33:39
difference compared to a standard steroid injection
33:42
alone. There are also a few other non -operative
33:45
therapies being explored, things like whole -body
33:47
cryotherapy, WBC, using extreme cold for anti
33:51
-inflammatory and analgesic effects, potentially
33:53
improving pain, ROM, and function. And even botulinum
33:57
toxin type A, Bontier injections, are being looked
33:59
at as an alternative to steroids, showing maybe
34:01
similar short -term effects, but at a considerably
34:04
higher cost, so its role is still really being
34:06
defined. That's a really comprehensive array
34:08
of non -operative options, but inevitably, sometimes
34:11
these measures just aren't enough. If conservative
34:14
management isn't yielding the desired results
34:16
after a decent trial, When do we start considering
34:19
surgical intervention? And what are the primary
34:22
techniques involved? This must feel like quite
34:24
a significant step for patients. It is a significant
34:27
step and rightly so. Surgical interventions are
34:30
generally reserved for patients with persistent
34:32
disabling symptoms that have proven refractory
34:34
unresponsive to a prolonged course of non -operative
34:38
modalities. Typically, we're looking at a period
34:40
of, say, three to six months of dedicated conservative
34:43
management, perhaps slightly shorter, maybe six
34:46
to 12 weeks if symptoms are severe. and continue
34:48
unabated despite a rigorous non -operative regimen.
34:52
Surgery is most often considered and offered
34:54
during that frozen or stage two phase of the
34:57
condition where stiffness is the predominant
34:59
issue and the acute intense pain has usually
35:02
subsided somewhat. Okay, so timing matters. What
35:04
are the options? The first surgical option often
35:07
discussed is manipulation under anesthesia, MUA.
35:10
The procedure itself involves, quite literally,
35:13
manipulating the shoulder joint aggressively
35:15
while the patient is fully anesthetized and their
35:18
muscles are completely relaxed. The goal is to
35:21
forcibly tear the adhesions and stretch that
35:24
contracted capsule beyond the normal pain thresholds,
35:27
something impossible to achieve while the patient
35:29
is awake. Sounds quite forceful. It is. And while
35:32
often regarded as relatively safe when done carefully,
35:35
it carries notable risks. These include potential
35:38
complications like humeral fractures, glenohumeral
35:40
joint dislocation, tearing the rotator cuff tendons
35:43
or the labrum, and even brachial plexus nerve
35:46
palsies, stretch injuries to the nerves. These
35:49
are more likely if the manipulation is perhaps
35:51
overzealous or if the patient has underlying
35:53
osteoporotic bone which is more fragile. Bleeding
35:56
into the joint, hemothorosis, can also occur.
35:58
These are not insignificant risks and need careful
36:01
discussion. Absolutely, and how effective is
36:03
it? Well, its effectiveness is actually somewhat
36:06
controversial. It's generally not recommended
36:08
during the very early inflammatory freezing phase
36:11
as you might just stir things up and make the
36:14
inflammation worse. Furthermore, MUA has been
36:16
shown to be significantly less effective in diabetic
36:19
patients, with some studies reporting failure
36:21
rates as high as 50%. There are even studies
36:23
suggesting that MUA combined with home exercises
36:26
provides pretty comparable outcomes to just home
36:29
exercises alone, or that pharmacotherapy and
36:31
physiotherapy might yield better subjective results
36:34
than MUA in some patient groups. So it's certainly
36:37
not a guaranteed fix, and its role is perhaps
36:40
diminishing slightly compared to other techniques.
36:42
OK, so MUA has its place, but also limitations
36:45
and risks. What's the alternative? The second
36:47
and increasingly preferred surgical option is
36:50
arthroscopic capsular release. This is generally
36:53
considered a highly effective and safe method
36:55
for treating resistant adhesive capsulitis. Its
36:58
key advantages are quite significant. Firstly,
37:01
it allows the surgeon to look directly inside
37:03
the joint with a camera arthroscopy. This confirms
37:07
the diagnosis visually and, importantly, allows
37:09
us to rule out any other potential pathologies
37:12
that might have been missed with non -invasive
37:14
imaging. Secondly, and critically, it allows
37:17
the surgeon to directly see and precisely release
37:19
the tightened structures, specifically the corca
37:21
humeral ligament, the thickened rotator interval,
37:24
and the contracted capsule itself. This ensures
37:27
an adequate release under direct vision, which
37:29
is a major advantage over a blind manipulation.
37:32
More targeted and controlled. Exactly. The technique
37:35
typically involves using specialized instruments
37:37
through small keyhole incisions to release those
37:40
tight intra -articular structures. The focus
37:43
is often on releasing the rotator interval from
37:45
the front of the biceps tendon down to the top
37:48
edge of the subscapularis tendon, and specifically
37:51
releasing that thickened coricohumeral ligament.
37:54
Sometimes a posterior capsular release is also
37:56
performed to help improve internal rotation and
37:59
cross -body adduction. A subchromial persectomy
38:02
removing inflamed bursa tissue, and releasing
38:04
any adhesions there might be done as needed,
38:07
though anacromioplasty, shaving bone, is generally
38:10
not indicated just for adhesive capsulitis. In
38:13
many cases, a surgeon might combine the arthroscopic
38:15
release with a gentle MUA at the end to ensure
38:18
maximum range of motion is achieved, but this
38:20
is done very judiciously after the capsule has
38:22
been released. and recovery after this procedure.
38:25
Recovery from arthroscopic capsular release absolutely
38:28
necessitates immediate early and quite aggressive
38:31
post -operative physical therapy. This is crucial
38:34
to maintain the motion that was achieved during
38:35
the surgery. Without it, the scar tissue can
38:38
reform and the gains can quickly be lost. Recovery
38:41
times typically range from about six weeks to
38:44
three months for significant functional improvement.
38:46
So the physiotherapy post -op is non -negotiable.
38:49
Absolutely non -negotiable. In terms of outcomes,
38:52
most patients have good results with reduced
38:54
pain and significantly improved range of motion.
38:57
Long -term outcomes are generally positive. However,
39:00
some degree of stiffness can persist, even after
39:03
a successful release. And again, diabetic patients
39:06
frustratingly often continue to experience some
39:09
degree of stiffness even after surgical intervention,
39:12
reinforcing that systemic influence. Recurrence
39:15
of stiffness is possible, perhaps up to around
39:17
11 % at one year in some series. Factors like
39:20
being female over 50 and having type 2 diabetes
39:23
tend to correlate with less favorable outcomes
39:25
post -surgery, which highlights the need for
39:27
careful preoperative counseling about realistic
39:29
expectations. Important factors to consider.
39:33
What about complications? Complications are generally
39:35
less common than with MUA alone. The primary
39:39
specific concern with arthroscopic release is
39:41
potential injury to the axillary nerve. This
39:44
nerve runs quite close to the inferior aspect
39:47
of the capsule. Therefore, performing the inferior
39:50
release carefully, often staying close to the
39:52
glenoid rim, the socket, is essential to mitigate
39:55
this risk. Surgical site infection is a very
39:58
rare but possible general surgical complication.
40:01
Other risks like fracture or brachial plexopathy
40:05
are much more associated with the MUA component
40:07
if that's performed concurrently and perhaps
40:09
too forcefully. Lastly, just to mention open
40:12
capsulotomy. This involves a larger incision
40:15
to release the capsule. It's rarely performed
40:17
nowadays because the arthroscopic techniques
40:19
offer smaller wounds, generally shorter recovery
40:21
times, and comparable effectiveness. However,
40:24
it remains an option, perhaps if arthroscopic
40:26
release fails to achieve the desired outcome
40:28
for some reason. Okay. And you mentioned physiotherapy
40:31
being key. Post -op pain management must be vital
40:33
too. Absolutely vital. Post -operative pain management
40:36
is crucial for success. Adequate pain control,
40:39
perhaps achieved using methods like an intra
40:41
-articular pain catheter delivering local anesthetic,
40:44
sometimes a cervical epidural infusion, or more
40:47
commonly, an interscale nerve block placed preoperatively
40:50
is absolutely essential. This isn't just about
40:53
patient comfort, although that's important. Effective
40:55
pain relief directly enables patients to comfortably
40:57
engage in that immediate essential post -operative
41:00
physical therapy. Without good pain control,
41:03
they simply won't be able to tolerate the exercises
41:05
needed to maintain the surgically achieved motion
41:07
and prevent recurrence of the arthrofibrosis.
41:10
It's an absolutely key piece of the post -operative
41:13
puzzle. It's certainly clear that the treatment
41:18
pathway, especially when it involves surgery,
41:21
requires really meticulous planning and execution,
41:24
including that postdoc phase. Now, looking at
41:27
the long game, what can patients generally expect
41:29
in terms of their recovery journey? What factors
41:32
might influence the ultimate outcome? What's
41:35
the overall prognosis for adhesive capsulitis?
41:37
And how should we be counseling our patients
41:39
about this? The prognosis for adhesive capsulitis
41:41
is, generally speaking, pretty good. particularly
41:44
if it's diagnosed reasonably early and managed
41:46
appropriately. It is, as we've established, fundamentally
41:49
a self -limited disease. It tends to resolve
41:52
on its own over time. But for the patient, this
41:55
recovery typically occurs over a lengthy span,
41:58
usually one to three years. That's a long time
42:01
for someone to be in pain or significantly limited
42:03
functionally. Three years is a huge chunk of
42:05
life. It really is. And while approximately 80
42:08
% of patients do regain near normal or normal
42:10
shoulder function with proper treatment, it's
42:12
really important to manage expectations. Complete
42:15
recovery, meaning a full, unrestricted return
42:18
to their preconditioned motion and function,
42:20
is actually infrequent. Around 10 % to 20 % of
42:23
patients may still experience some residual symptoms,
42:26
including a degree of stiffness and perhaps some
42:28
discomfort, even after the acute phases have
42:31
passed. This means they might not fully regain
42:33
the range of motion they had before it started,
42:35
and that's something we must communicate clearly
42:37
and realistically to them. So tempering expectations
42:41
is key. Absolutely. And crucially, individuals
42:44
with those comorbid conditions we discussed,
42:47
particularly diabetes, mellitus, or thyroid dysfunction,
42:49
commonly have a longer and often more severe
42:51
course of adhesive capsulitis. This inevitably
42:54
leads to a less favorable prognosis overall.
42:57
We consistently see that diabetic patients, even
42:59
after surgical intervention, often have continued
43:02
shoulder stiffness, highlighting the profound
43:04
systemic influence of these underlying diseases
43:06
on their recovery potential. Their journey is
43:09
often more arduous and the endpoint less complete.
43:11
That's a sobering reality for those patients.
43:14
It is. And beyond the purely physical aspects,
43:17
we absolutely must consider the psychological
43:19
factors. These play a significant and often underestimated
43:23
role in the patient's experience and outcome.
43:27
Things like pain -related fear, anxiety, and
43:29
depression can profoundly influence patient reported
43:32
outcomes, their perceived shoulder function,
43:34
their level of disability, and their overall
43:36
pain experience. Patients frequently report feelings
43:39
of intense frustration, a significant loss of
43:42
independence due to the limitations imposed by
43:44
the condition. They can feel quite isolated.
43:47
It affects their whole life, not just their shoulder.
43:49
Precisely. These emotional and psychological
43:51
burdens can exacerbate their distress and negatively
43:54
impact their willingness and ability to engage
43:56
fully with therapy, thereby influencing their
43:59
ultimate physical prognosis. It's a condition
44:01
that truly impacts much more than just the joint
44:04
itself. That's such a powerful reminder of the
44:07
holistic nature of patient care. And of course,
44:10
no medical condition or intervention is entirely
44:12
without its complexities or potential downsides.
44:15
What are the potential complications we need
44:17
to be aware of, both from the condition itself
44:19
and from the various treatments we've discussed?
44:21
What should we be explicitly discussing with
44:23
patients as part of the informed consent process?
44:26
That's a vital consideration for ensuring truly
44:28
shared decision making with our patients. First,
44:31
let's look at potential complications arising
44:33
from the condition itself. itself. The most common
44:35
issues are simply the persistence of residual
44:37
shoulder pain and stiffness. As we just discussed,
44:40
this can last long after the primary phases are
44:42
expected to have resolved, becoming a source
44:44
of ongoing frustration and limitation. Also,
44:48
prolonged immobility due to the condition can
44:51
lead to significant deconditioning of the shoulder
44:53
girdle muscles. This can make the shoulder more
44:55
vulnerable to additional injuries down the line.
44:58
We sometimes see secondary issues like labral
45:00
tears or even rotator cuff tears developing,
45:03
possibly due to excessive stress on the capsule
45:05
and adjacent structures as patients try to compensate
45:08
or force movement through the stiff joint. Okay,
45:11
so the condition itself has long -term implications.
45:14
What about the treatments? Now regarding complications
45:16
arising from treatments. With manipulation under
45:19
anesthesia, MUA, the risks are perhaps more acute
45:22
and potentially more severe due to the forceful
45:25
nature of the procedure. These include serious
45:27
concerns such as humeral fractures, breaking
45:29
the arm bone, biceps or subscapularis tendon
45:32
ruptures, glenohumeral joint dislocation, the
45:35
shoulder popping out, and rotator cuff tears.
45:38
There's also that risk of brachial plexus palsy
45:41
nerve injuries, particularly following overzealous
45:44
manipulation or in patients with fragile osteoporotic
45:47
bone. These are significant potential complications
45:50
that demand a very frank discussion beforehand.
45:53
For arthroscopic capsular release, While generally
45:55
considered safer due to the controlled nature
45:57
of the release, the primary specific concern
45:59
is axillary nerve injury. As mentioned, this
46:02
nerve runs close to the inferior capsule. Careful
46:04
surgical technique, especially during the inferior
46:06
release near the glenoid rim, is essential to
46:08
minimize this risk. Surgical site infection is
46:11
a very rare but possible general surgical complication
46:13
with any arthroscopic procedure. And overall,
46:16
patients, especially those with diabetes, may
46:19
still experience residual stiffness even after
46:21
a technically successful surgery, as we noted
46:23
when discussing prognosis. The key is to be aware
46:26
of these risks, discuss them openly with patients,
46:29
tailor the treatment approach appropriately,
46:31
and set realistic expectations from the outset.
46:33
That brings us really nicely to how we as healthcare
46:37
professionals can best support our patients through
46:39
what is clearly a challenging condition going
46:42
beyond just the clinical procedures. How does
46:45
the interprofessional healthcare team ideally
46:47
come together to optimize outcomes? It seems
46:50
absolutely clear that this isn't a condition
46:52
for isolated practitioners. That team approach
46:54
feels critical here. You've hit on an absolutely
46:58
crucial point. This really gets to the heart
47:00
of delivering effective patient -centered care
47:02
for a condition like adhesive capsulitis. It's
47:06
definitely not just about the specific medical
47:08
or surgical interventions. It's about supporting
47:10
the whole person through their journey. So what
47:11
does that look like in practice? Well, first
47:13
and foremost, patient education is absolutely
47:15
vital. Providing patients with clear, concise
47:18
explanations of adhesive capsulitis, what it
47:21
is, its characteristic pain and stiffness, and
47:24
importantly, its natural progression through
47:26
those freezing, frozen, and thawing phases is
47:29
fundamental. This foundational understanding
47:32
helps manage their expectations, which is huge.
47:35
It reduces the often significant anxiety they
47:37
experience. What's wrong with me? Will it ever
47:39
get better? and profoundly improves their compliance
47:42
with treatment protocols, particularly the often
47:45
lengthy physiotherapy. Patients often feel disempowered
47:48
or deeply frustrated if they don't understand
47:50
why they're experiencing what they are or how
47:52
long it might realistically last. An empathetic
47:55
explanation of the long and variable course of
47:57
the disease really empowers them. Setting the
48:00
stage for the journey ahead. Exactly. We also
48:03
need to stress preventive measures where possible.
48:05
This includes ensuring prompt recovery of shoulder
48:08
mobility after any injury or surgery, actively
48:11
preventing the prolonged immobilization that
48:13
can trigger this condition in susceptible individuals.
48:17
Effective management of underlying systemic diseases,
48:20
particularly diabetes through optimizing HbO1c
48:22
levels, is also a key preventive or management
48:24
strategy. Encouraging regular participation in
48:27
customized exercise programs to maintain general
48:30
shoulder mobility and strength is crucial for
48:32
everyone, but especially those at higher risk.
48:34
An early intervention should be initiated whenever
48:36
prolonged immobility is anticipated, for example
48:39
after a fracture requiring immobilization. Proactive
48:42
steps were possible. Precisely. Now achieving
48:45
truly enhanced healthcare team outcomes absolutely
48:48
demands a collaborative interprofessional approach.
48:52
No single clinician can effectively manage this
48:55
condition in isolation. It really takes a village.
48:58
Primary care clinicians are often the first point
49:00
of contact. They're responsible for that initial
49:03
evaluation, making crucial initial management
49:06
decisions, and knowing when to make a timely
49:08
referral to specialists like orthopedic surgeons
49:10
or pain management teams. Physical therapists
49:13
play such a critical, hands -on role. They guide
49:16
patients through the specific exercises for pain
49:18
reduction and mobility improvement, developing
49:21
individualized rehabilitation protocols. They
49:23
are often the daily guides for the patient on
49:25
their recovery journey. They're really central,
49:27
aren't they? Hugely central. Occupational therapists
49:30
are also essential, particularly when function
49:32
is severely limited. They provide practical strategies
49:35
to help patients improve their performance of
49:38
daily activities affected by the shoulder dysfunction.
49:41
Things like dressing, personal care, cooking,
49:44
helping them adapt and maintain as much independence
49:46
as possible. Nurses especially practice nurses
49:49
or specialist nurses, are crucial for providing
49:52
ongoing patient information, support, monitoring
49:55
progress, and often being that consistent point
49:58
of contact for patient queries and concerns.
50:01
Orthopedic specialists step in primarily for
50:03
diagnostic clarification in complex cases and
50:06
for surgical intervention when conservative measures
50:08
are no longer sufficient, offering their specific
50:11
expertise in those procedures. And pain management
50:13
teams can be essential, particularly in severe
50:16
or refractory cases. As we've discussed, effective
50:19
pain control is what allows patients to actively
50:21
participate in their physical therapy, which
50:23
is absolutely non -negotiable for recovery. Without
50:26
adequate pain control, therapy can become impossible
50:29
or ineffective. It's a real multidisciplinary
50:31
effort. It has to be. And underpinning all of
50:34
this is effective communication and collaboration
50:37
among these professionals. This means utilizing
50:39
shared electronic health records effectively,
50:42
maintaining open lines of communication, picking
50:45
up the phone, and ideally having mechanisms for
50:48
regular team updates or meetings to ensure everyone
50:51
is aligned on the patient's progress, their response
50:53
to treatment, and the overall management plan.
50:56
This coordinated care ensures consistency and
50:59
adherence to current clinical guidelines. And
51:01
finally, we must always underscore the profound
51:04
psychological impact and the importance of support
51:06
networks and true patient -centered care. We
51:09
need to actively acknowledge and validate the
51:11
patient's experience, address their often unspoken
51:14
feelings of frustration, sometimes even shame
51:16
about their limitations, and that significant
51:18
loss of independence they often report. Prioritizing
51:21
effective pain management isn't just about physical
51:24
comfort. It significantly improves psychological
51:26
well -being. When pain is better controlled,
51:28
patients feel more empowered, less anxious, and
51:31
more able to engage fully and effectively in
51:33
their physical therapies, which ultimately leads
51:35
to better overall outcomes. It really is about
51:38
treating the person, not just the shoulder joint,
51:41
and recognizing the very real burden this condition
51:44
places on their entire life. That's such a powerful
51:46
call for integrated empathetic care, really acknowledging
51:50
the full scope of the patient's experience. It's
51:53
so important. As we start to wrap up our deep
51:55
dive into adhesive capsulitis, perhaps looking
51:58
to the future, what's on the horizon, both for
52:01
understanding its pathophysiology even better
52:03
and perhaps for developing even more effective
52:06
treatments. Where is the research heading? Yes,
52:09
the future of adhesive capsulitis management
52:11
is certainly an active area of research, which
52:13
is encouraging. There's a definite push towards
52:16
developing novel non -operative therapeutic interventions
52:19
that specifically target the underlying inflammatory
52:22
or fibrotic processes, moving beyond just symptomatic
52:25
relief toward actually modifying the disease
52:28
process itself. Targeting the root cause more
52:30
directly. That's the goal. One particularly interesting
52:33
area is enzymatic capsulotomy, using enzymes
52:36
like collagenase. Collagenase is an enzyme derived
52:39
from a bacterium Clostridium histolyticum that
52:42
specifically breaks down the peptide bonds in
52:44
collagen. It's already FDA -approved and used
52:47
clinically for other fibrotic disorders like
52:50
Dupotter's disease in the hand and Peroni's disease,
52:53
both of which share some histological and molecular
52:55
similarities with the fibrosis seen in adhesive
52:57
capsulitis. So using an enzyme to dissolve the
53:01
scar tissue. That's the principle, yes. Early
53:04
studies are now investigating the off -label
53:05
use of collagenase injections directly into the
53:08
shoulder joint for adhesive capsulitis. Initial
53:11
results seem promising, showing potential improvements
53:13
in functional scores, shoulder motion, and pain.
53:16
Now these are still in the relatively early phases
53:18
of research, needing larger trials to confirm
53:21
safety and efficacy. But the concept of directly
53:23
breaking down that excessive fibrotic tissue
53:26
rather than just mechanically stretching it or
53:28
suppressing inflammation is certainly compelling.
53:30
It represents a potential paradigm shift in treatment
53:33
if proven successful. That sounds very promising
53:35
indeed. Anything else on the horizon? Another
53:38
area that has been considered is the exploration
53:40
of anti -TNF agents. These are drugs that target
53:43
tumor necrosis factor alpha, a key inflammatory
53:46
cytokine. While these agents are well established
53:49
and effective in treating other inflammatory
53:51
conditions like rheumatoid arthritis, their application
53:54
specifically in adhesive capsulitis hasn't been
53:57
well studied to date. Some initial pilot studies
53:59
have actually shown limited or no efficacy currently.
54:02
This might suggest that the inflammatory pathways
54:04
driving adhesive capsulitis are perhaps more
54:07
complex or involve different primary mediators
54:10
than those effectively targeted by the current
54:12
anti -TNF drugs. So that particular avenue requires
54:16
more nuanced investigation to see if there's
54:18
a role perhaps for different anti cytokine therapies.
54:21
So maybe not TNF but other inflammatory targets?
54:23
Potentially. And beyond specific pharmacological
54:27
agents, there's a significant ongoing focus on
54:29
developing and utilizing better, more validated
54:32
animal models of adhesive capsulitis. Historically,
54:36
research progress has been hampered somewhat
54:38
by the lack of good animal models that accurately
54:40
replicate the human condition. However, newer
54:44
models, for instance involving specific types
54:45
of shoulder immobilization in rats or rabbits,
54:48
are now showing more promise in replicating the
54:50
key features we see in humans, the progressive
54:52
loss of range of motion, the capsular adhesions,
54:55
the specific collagen accumulation patterns.
54:57
These improved models, which allow for more detailed
55:00
molecular studies and long -term functional measurements,
55:03
are crucial. They pave the way for more rigorous
55:05
pre -clinical testing of new pharmacological
55:08
therapies, and will undoubtedly provide deeper
55:10
insights into the complex disease mechanisms.
55:13
Hopefully this will lead to more targeted and
55:14
effective treatments emerging in the coming years.
55:16
That's certainly encouraging to hear about the
55:18
ongoing research and the potential for new therapeutic
55:21
avenues. As we conclude our discussion today,
55:24
what would you say are the absolute key clinical
55:27
pearls you'd like our listeners, our colleagues
55:29
who are mid senior medical professionals, to
55:32
really take away and remember about managing
55:34
this challenging condition in their day -to -day
55:36
practice? What are the non -negotiables from
55:39
this deep dive? Certainly. If I were to distill
55:41
our conversation down into the most important
55:43
clinical insights for the practicing professional
55:45
managing adhesive capsulitis, I'd highlight these
55:47
points. First, the hallmark trait. Remember the
55:50
significant loss of both passive and active range
55:53
of motion, particularly external rotation, is
55:55
key. If passive motion is largely preserved,
55:58
think very carefully it's probably not adhesive
56:00
capsulitis. Second, pathophysiology. Keep in
56:03
mind that complex interplay of initial inflammation
56:06
leading to progressive fibrosis within the joint
56:08
capsule and synovium. Understanding this helps
56:11
inform treatment timing and rationale why aggressive
56:13
stretching might hurt early on, and why future
56:16
therapies might target fibrosis directly. Third,
56:19
diagnosis. It remains primarily a clinical diagnosis
56:22
based on history and examination. Imaging, like
56:25
x -ray and sometimes MRI, is crucial mainly to
56:27
rule out other underlying pathologies, not necessarily
56:30
to definitively diagnose adhesive capsulitis
56:32
itself. Likewise, laboratory testing is for investigating
56:35
associated systemic diseases like diabetes or
56:37
thyroid issues, not for a direct marker of the
56:40
shoulder condition. Fourth, prognosis. Counsel
56:43
patients that while it's generally self -limiting,
56:45
the course is often prolonged months to years.
56:48
Manage their expectations accordingly. Be especially
56:51
mindful that patients with diabetes commonly
56:53
experience worse outcomes and more persistent
56:55
stiffness, even after surgery, making their management
56:58
particularly challenging and requiring specific
57:00
counseling. Fifth. The treatment cornerstone.
57:05
Physiotherapy remains the primary treatment modality,
57:08
focused on gentle, progressive stretching, often
57:10
in conjunction with effective pain management
57:12
strategies. Conservative management should always
57:15
be the first line, with surgery reserved for
57:17
refractory cases considered at the appropriate
57:19
stage, usually stage two. Fifth, the treatment
57:23
cornerstone. And finally, always embrace a holistic
57:26
approach. Recognize the critical role of interprofessional
57:29
collaboration, working closely with physios,
57:31
OTs, pain teams, and combine this with comprehensive
57:34
patient education and robust psychological support.
57:38
This integrated approach is paramount to achieving
57:40
optimal outcomes and effectively managing patient
57:42
expectations throughout their often frustrating
57:44
journey. Remember to treat the patient, not just
57:47
the shoulder. Professor Imam, thank you so much
57:50
for guiding us through the complexities of adhesive
57:52
capsulitis today with such remarkable clarity
57:55
and invaluable insight. Your expertise has truly
57:59
illuminated this challenging condition for us
58:01
and I'm sure for everyone listening. To our listeners,
58:04
we really hope this deep dive has provided you
58:06
with a clearer, perhaps more nuanced understanding
58:09
of adhesive capsulitis. We hope it's equipped
58:11
you with practical insights to better support
58:13
your patients and navigate this often difficult
58:15
condition more effectively in your practice.
58:18
If you found this discussion valuable, please
58:20
do take just a moment to rate and share the deep
58:22
dive. Your feedback and sharing truly helps us
58:25
reach more curious minds like yours in the medical
58:27
community, allowing us to continue providing
58:29
these in -depth explorations. Thank you so much
58:31
for joining us and we look forward to our next
58:33
deep dive.